[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2353285A1 - Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action - Google Patents

Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action

Info

Publication number
FR2353285A1
FR2353285A1 FR7528462A FR7528462A FR2353285A1 FR 2353285 A1 FR2353285 A1 FR 2353285A1 FR 7528462 A FR7528462 A FR 7528462A FR 7528462 A FR7528462 A FR 7528462A FR 2353285 A1 FR2353285 A1 FR 2353285A1
Authority
FR
France
Prior art keywords
compsn
angina pectoris
reduced side
showing
side effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7528462A
Other languages
French (fr)
Other versions
FR2353285B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DOMS LABORATOIRES
Original Assignee
DOMS LABORATOIRES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DOMS LABORATOIRES filed Critical DOMS LABORATOIRES
Priority to FR7528462A priority Critical patent/FR2353285A1/en
Publication of FR2353285A1 publication Critical patent/FR2353285A1/en
Application granted granted Critical
Publication of FR2353285B1 publication Critical patent/FR2353285B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

coronary vasodilator compsn. comprising granules, not more than 2mm. in dia. of dipyridamole enclosed in a film, insoluble or only slightly soluble in water at 37 degrees C, which swells in contact with water and is degradable by man. The compsn. shows reduced side-effects such as headache, intestinal disorders and dizziness and also suppresses angina pectoris. Pref. film thickness is 0.1-200 mu m. When the interior of the granule comprises dipyridamol alone, it is to a concn. of 60-95%. It is pref. deposited on a biodegradable carrier such as starch, protein and esp. paraffins and stearin. Suitable film-formers are gelatin, ethylcellulose, polyvinyl alcohols, polyvinylpyrrolidone, polyamides etc. Pref. release time of the dipyridamol is 4-8 hr.
FR7528462A 1975-09-17 1975-09-17 Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action Granted FR2353285A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7528462A FR2353285A1 (en) 1975-09-17 1975-09-17 Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7528462A FR2353285A1 (en) 1975-09-17 1975-09-17 Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action

Publications (2)

Publication Number Publication Date
FR2353285A1 true FR2353285A1 (en) 1977-12-30
FR2353285B1 FR2353285B1 (en) 1978-12-01

Family

ID=9160081

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7528462A Granted FR2353285A1 (en) 1975-09-17 1975-09-17 Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action

Country Status (1)

Country Link
FR (1) FR2353285A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430766A1 (en) * 1978-07-15 1980-02-08 Boehringer Sohn Ingelheim DELAYED DRUG FORM COMPRISING AN INSOLUBLE POROUS BROADCASTING ENVELOPE
FR2432313A1 (en) * 1978-08-01 1980-02-29 Foulhoux Pierre Micro:granules contg. beta-histine - for controlled release and less side effects useful in treating Menieres syndrome
FR2452923A2 (en) * 1979-04-02 1980-10-31 Panoz Donald Controlled release oral galenical formulation - contains active components in micro-granules prepd. under high compression
EP0032562A1 (en) * 1980-01-12 1981-07-29 Dr. Karl Thomae GmbH Dipyridamol retard-forms and process for their preparation
EP0076428A1 (en) * 1981-10-05 1983-04-13 Tanabe Seiyaku Co., Ltd. Microcapsules and method of preparing same
EP0140255A2 (en) * 1983-10-14 1985-05-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release injections
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
WO2002049650A2 (en) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
WO2002049649A2 (en) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
WO2002049651A1 (en) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
WO2005044244A2 (en) * 2003-11-07 2005-05-19 Ernst-Moritz-Arndt- Universität Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430766A1 (en) * 1978-07-15 1980-02-08 Boehringer Sohn Ingelheim DELAYED DRUG FORM COMPRISING AN INSOLUBLE POROUS BROADCASTING ENVELOPE
FR2432313A1 (en) * 1978-08-01 1980-02-29 Foulhoux Pierre Micro:granules contg. beta-histine - for controlled release and less side effects useful in treating Menieres syndrome
US4726951A (en) * 1978-12-22 1988-02-23 Elan Corporation P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
FR2452923A2 (en) * 1979-04-02 1980-10-31 Panoz Donald Controlled release oral galenical formulation - contains active components in micro-granules prepd. under high compression
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
EP0032562A1 (en) * 1980-01-12 1981-07-29 Dr. Karl Thomae GmbH Dipyridamol retard-forms and process for their preparation
EP0032562B1 (en) * 1980-01-12 1984-03-14 Dr. Karl Thomae GmbH Dipyridamol retard-forms and process for their preparation
EP0076428A1 (en) * 1981-10-05 1983-04-13 Tanabe Seiyaku Co., Ltd. Microcapsules and method of preparing same
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
EP0140255A3 (en) * 1983-10-14 1985-10-30 Sumitomo Chemical Company, Limited Sustained-release injections
US5021241A (en) * 1983-10-14 1991-06-04 Sumitomo Pharmaceuticals Company, Limited Long-term sustained-release preparation
EP0140255A2 (en) * 1983-10-14 1985-05-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release injections
WO2002049650A2 (en) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
WO2002049649A2 (en) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
WO2002049651A1 (en) * 2000-12-19 2002-06-27 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
WO2002049650A3 (en) * 2000-12-19 2002-10-31 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
WO2002049649A3 (en) * 2000-12-19 2002-11-21 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
WO2005044244A2 (en) * 2003-11-07 2005-05-19 Ernst-Moritz-Arndt- Universität Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases
WO2005044244A3 (en) * 2003-11-07 2006-10-05 Univ Ernst Moritz Arndt Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases

Also Published As

Publication number Publication date
FR2353285B1 (en) 1978-12-01

Similar Documents

Publication Publication Date Title
FR2353285A1 (en) Coronary vasodilator controlled release dipyridamole compsn. - comprises film coated granules giving reduced side effects and also showing angina pectoris suppressing action
NL7607720A (en) PROCESS FOR THE PREPARATION OF A RELEASING AGENT AND ARTICLES CONTAINING A SUCH RELEASING AGENT.
NL7608368A (en) PROCESS FOR THE PREPARATION OF A COATING COMPOSITION.
NL185278C (en) METHOD FOR PREPARING AN LUMINOUS PYROTECHNICAL PREPARATION.
AU1507976A (en) 16 phencxy frosta 4, 5, 13 trienoic acid derivatives
NL7613482A (en) PROCESS FOR THE PREPARATION OF A COATING MATERIAL.
NL7601117A (en) PROCESS FOR THE PREPARATION OF ACETYLENE LENDERISES FROM AMINO ACIDS.
AU506606B2 (en) Articles for providing sustained release of water-soluble chemicals
NL178889C (en) PROCESS FOR THE PREPARATION OF A WATER-INsoluble ENZYME PREPARATION.
USD244182S (en) Camper shell
NL7714351A (en) PROCESS FOR THE PREPARATION OF A METHYL ESTER OF X-L-ASPARTYL-L-PHENYLALANINE.
USD242641S (en) Ghost figure doll
USD242933S (en) Pipe sculpture
NL7608064A (en) PROCESS FOR THE PREPARATION OF A PEPTIDE.
NL189291C (en) Process for the preparation of a sodium or potassium salt of 3,3-dimethyl-2-oxobutyric acid.
NL7507119A (en) PROCESS FOR THE PREPARATION OF A HYDROXYLAMINE SALT.
NL7702486A (en) PROCESS FOR THE SEPARATION OF WATER FROM GAS MIXTURES FORMED IN A VINYL ACETATE PREPARATION.
NL7705380A (en) PROCESS FOR THE PREPARATION OF UNSATURATED CARBONIC ACIDS.
USD247290S (en) Trailer
NL7613067A (en) PROCESS FOR THE PREPARATION OF ETHYLAMINE DERIVARIES.
USD243865S (en) Game target
NL7609223A (en) PROCESS FOR THE PREPARATION OF A PROSTANE DERIVATIVE.
NL7613331A (en) PROCESS FOR THE PREPARATION OF A PHOSPHOLEN-1-GALCOGENIDE.
USD247984S (en) Doll house
NL7606177A (en) PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE OXAZOLE DERIVATIVE.

Legal Events

Date Code Title Description
ST Notification of lapse